B7-H4 expression in renal cell carcinoma and tumor vasculature

Associations with cancer progression and survival

Amy Krambeck, R. Houston Thompson, Haidong Dong, Christine M. Lohse, Eugene S. Park, Susan M. Kuntz, Bradley C. Leibovich, Michael L. Blute, John C. Cheville, Eugene D. Kwon

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

B7-H4 is a recently described B7 family coregulatory ligand that has been implicated as an inhibitor of T cell-mediated immunity. Although expression of B7-H4 is typically limited to lymphoid cells, aberrant B7-H4 expression has also been reported in several human malignancies. To date, associations of B7-H4 with clinical outcomes for cancer patients are lacking. Therefore, we examined B7-H4 expression in fresh-frozen tumor specimens from 259 renal cell carcinoma (RCC) patients treated with nephrectomy between 2000 and 2003 and performed correlative outcome analyses. We report that 153 (59.1%) RCC tumor specimens exhibited B7-H4 staining and that tumor cell B7-H4 expression was associated with adverse clinical and pathologic features, including constitutional symptoms, tumor necrosis, and advanced tumor size, stage, and grade. Patients with tumors expressing B7-H4 were also three times more likely to die from RCC compared with patients lacking B7-H4 (risk ratio = 3.05; 95% confidence interval = 1.51-6.14; P = 0.002). Additionally, 211 (81.5%) specimens exhibited tumor vasculature endothelial B7-H4 expression, whereas only 6.5% of normal adjacent renal tissue vessels exhibited endothelial B7-H4 staining. Based on these findings, we conclude that B7-H4 has the potential to be a useful prognostic marker for patients with RCC. In addition, B7-H4 represents a target for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment of RCC tumors. Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC.

Original languageEnglish (US)
Pages (from-to)10391-10396
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number27
DOIs
StatePublished - Jul 4 2006
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Survival
Neoplasms
Staining and Labeling
Nephrectomy
Cellular Immunity
Necrosis
Odds Ratio
Lymphocytes
Confidence Intervals
Ligands
T-Lymphocytes
Kidney

Keywords

  • B7-H1
  • Costimulation
  • Immunotherapy
  • Kidney neoplasms
  • Tumor biomarker

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

B7-H4 expression in renal cell carcinoma and tumor vasculature : Associations with cancer progression and survival. / Krambeck, Amy; Thompson, R. Houston; Dong, Haidong; Lohse, Christine M.; Park, Eugene S.; Kuntz, Susan M.; Leibovich, Bradley C.; Blute, Michael L.; Cheville, John C.; Kwon, Eugene D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 27, 04.07.2006, p. 10391-10396.

Research output: Contribution to journalArticle

Krambeck, Amy ; Thompson, R. Houston ; Dong, Haidong ; Lohse, Christine M. ; Park, Eugene S. ; Kuntz, Susan M. ; Leibovich, Bradley C. ; Blute, Michael L. ; Cheville, John C. ; Kwon, Eugene D. / B7-H4 expression in renal cell carcinoma and tumor vasculature : Associations with cancer progression and survival. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 27. pp. 10391-10396.
@article{638014da382e44429c5f4ed6b6d9f58f,
title = "B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival",
abstract = "B7-H4 is a recently described B7 family coregulatory ligand that has been implicated as an inhibitor of T cell-mediated immunity. Although expression of B7-H4 is typically limited to lymphoid cells, aberrant B7-H4 expression has also been reported in several human malignancies. To date, associations of B7-H4 with clinical outcomes for cancer patients are lacking. Therefore, we examined B7-H4 expression in fresh-frozen tumor specimens from 259 renal cell carcinoma (RCC) patients treated with nephrectomy between 2000 and 2003 and performed correlative outcome analyses. We report that 153 (59.1{\%}) RCC tumor specimens exhibited B7-H4 staining and that tumor cell B7-H4 expression was associated with adverse clinical and pathologic features, including constitutional symptoms, tumor necrosis, and advanced tumor size, stage, and grade. Patients with tumors expressing B7-H4 were also three times more likely to die from RCC compared with patients lacking B7-H4 (risk ratio = 3.05; 95{\%} confidence interval = 1.51-6.14; P = 0.002). Additionally, 211 (81.5{\%}) specimens exhibited tumor vasculature endothelial B7-H4 expression, whereas only 6.5{\%} of normal adjacent renal tissue vessels exhibited endothelial B7-H4 staining. Based on these findings, we conclude that B7-H4 has the potential to be a useful prognostic marker for patients with RCC. In addition, B7-H4 represents a target for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment of RCC tumors. Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC.",
keywords = "B7-H1, Costimulation, Immunotherapy, Kidney neoplasms, Tumor biomarker",
author = "Amy Krambeck and Thompson, {R. Houston} and Haidong Dong and Lohse, {Christine M.} and Park, {Eugene S.} and Kuntz, {Susan M.} and Leibovich, {Bradley C.} and Blute, {Michael L.} and Cheville, {John C.} and Kwon, {Eugene D.}",
year = "2006",
month = "7",
day = "4",
doi = "10.1073/pnas.0600937103",
language = "English (US)",
volume = "103",
pages = "10391--10396",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "27",

}

TY - JOUR

T1 - B7-H4 expression in renal cell carcinoma and tumor vasculature

T2 - Associations with cancer progression and survival

AU - Krambeck, Amy

AU - Thompson, R. Houston

AU - Dong, Haidong

AU - Lohse, Christine M.

AU - Park, Eugene S.

AU - Kuntz, Susan M.

AU - Leibovich, Bradley C.

AU - Blute, Michael L.

AU - Cheville, John C.

AU - Kwon, Eugene D.

PY - 2006/7/4

Y1 - 2006/7/4

N2 - B7-H4 is a recently described B7 family coregulatory ligand that has been implicated as an inhibitor of T cell-mediated immunity. Although expression of B7-H4 is typically limited to lymphoid cells, aberrant B7-H4 expression has also been reported in several human malignancies. To date, associations of B7-H4 with clinical outcomes for cancer patients are lacking. Therefore, we examined B7-H4 expression in fresh-frozen tumor specimens from 259 renal cell carcinoma (RCC) patients treated with nephrectomy between 2000 and 2003 and performed correlative outcome analyses. We report that 153 (59.1%) RCC tumor specimens exhibited B7-H4 staining and that tumor cell B7-H4 expression was associated with adverse clinical and pathologic features, including constitutional symptoms, tumor necrosis, and advanced tumor size, stage, and grade. Patients with tumors expressing B7-H4 were also three times more likely to die from RCC compared with patients lacking B7-H4 (risk ratio = 3.05; 95% confidence interval = 1.51-6.14; P = 0.002). Additionally, 211 (81.5%) specimens exhibited tumor vasculature endothelial B7-H4 expression, whereas only 6.5% of normal adjacent renal tissue vessels exhibited endothelial B7-H4 staining. Based on these findings, we conclude that B7-H4 has the potential to be a useful prognostic marker for patients with RCC. In addition, B7-H4 represents a target for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment of RCC tumors. Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC.

AB - B7-H4 is a recently described B7 family coregulatory ligand that has been implicated as an inhibitor of T cell-mediated immunity. Although expression of B7-H4 is typically limited to lymphoid cells, aberrant B7-H4 expression has also been reported in several human malignancies. To date, associations of B7-H4 with clinical outcomes for cancer patients are lacking. Therefore, we examined B7-H4 expression in fresh-frozen tumor specimens from 259 renal cell carcinoma (RCC) patients treated with nephrectomy between 2000 and 2003 and performed correlative outcome analyses. We report that 153 (59.1%) RCC tumor specimens exhibited B7-H4 staining and that tumor cell B7-H4 expression was associated with adverse clinical and pathologic features, including constitutional symptoms, tumor necrosis, and advanced tumor size, stage, and grade. Patients with tumors expressing B7-H4 were also three times more likely to die from RCC compared with patients lacking B7-H4 (risk ratio = 3.05; 95% confidence interval = 1.51-6.14; P = 0.002). Additionally, 211 (81.5%) specimens exhibited tumor vasculature endothelial B7-H4 expression, whereas only 6.5% of normal adjacent renal tissue vessels exhibited endothelial B7-H4 staining. Based on these findings, we conclude that B7-H4 has the potential to be a useful prognostic marker for patients with RCC. In addition, B7-H4 represents a target for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment of RCC tumors. Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC.

KW - B7-H1

KW - Costimulation

KW - Immunotherapy

KW - Kidney neoplasms

KW - Tumor biomarker

UR - http://www.scopus.com/inward/record.url?scp=33745886516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745886516&partnerID=8YFLogxK

U2 - 10.1073/pnas.0600937103

DO - 10.1073/pnas.0600937103

M3 - Article

VL - 103

SP - 10391

EP - 10396

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 27

ER -